Harmony Biosciences Holdings, Inc.

$29.53 ▼ -0.79%

2026-04-21 07:21:00

Explore Harmony Biosciences Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.

Market Cap

$1.73 B

Current Price

$29.53

52W High / Low

$40.87 / $25.52

Stock P/E

10.93

Book Value

$15.07

Dividend Yield

—

ROCE

20.45%

ROE

20.75%

Face Value

—

EPS

$2.71

Exp Qtr EPS

—

Sector

Healthcare

Industry

Biotechnology

Employees

293

Beta

0.89

Debt / Equity

19.45

Current Ratio

3.6

Quick Ratio

3.58

Forward P/E

4.99

Price / Sales

1.93

Enterprise Value

$1.06 B

EV / EBITDA

4.55

EV / Revenue

1.23

Rating

None

Target Price

$42

EPS Forecast (FY)

—

ABOUT

In essence, harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical This organization, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. In essence, this organization delivers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. In essence, it also is focused on developing Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In essence, in addition, This organization's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. In essence, further, it is focused on developing ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. In essence, additionally, This organization is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. In essence, this organization was formerly known as Harmony Biosciences II, Inc. In essence, and changed its name to Harmony Biosciences Holdings, Inc. In February 2020. Harmony Biosciences Holdings, Inc. In essence, was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. ROE at 20.75% based on the latest available annual data. ROCE at 20.45% using operating income and capital employed. Debt to equity stands at 0.19x. Operating margin is 15.82% on trailing numbers. Trailing twelve month sales are available in the dataset.

Pros

Healthy return on equity.
Efficient use of capital employed.
Balance sheet leverage appears manageable.
Short-term liquidity looks comfortable.
Strong operating margin profile.
Net margin remains healthy.
Valuation is not stretched on P/E basis.

Cons

Some data points may be missing or delayed because the source is not an official exchange feed.

Sift Stocks

S.No.	Name	Price	P.E.	Market Cap	Div Yld %	ROCE	ROE	52Week High/ Low	Book Value
1.	enGene Therapeutics Inc.	$8.53	—	$571.42 M	—	-65%	-46.07%	$12.25 / $2.65	$4.2
2.	Forte Biosciences, Inc.	$34.43	—	$674.68 M	—	-113.91%	-1.22%	$35.8 / $4.9	$4.71
3.	Actinium Pharmaceuticals, Inc.	$1.44	—	$42.98 M	—	-82.74%	-1.67%	$1.95 / $0.95	$0.25
4.	OS Therapies Incorporated	$1.38	—	$58.43 M	—	582.87%	614.26%	$2.57 / $1.15	$-0.16
5.	Enanta Pharmaceuticals, Inc.	$13.78	—	$409.17 M	—	-36.76%	-60.01%	$17.15 / $4.83	$4.36
6.	Bio-Techne Corporation	$59.22	116.91	$9.33 B	0.53%	10.19%	3.97%	$72.16 / $46.01	$12.9
7.	CG Oncology, Inc.	$70.4	—	$6.2 B	—	-25.08%	-21.67%	$73.56 / $19.47	$9.33

Quarterly Results

Figures shown in M / B

	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024
Sales	243.78 M	239.46 M	200.49 M	184.73 M	201.27 M	—
Operating Profit	38.56 M	65.49 M	48.18 M	56.24 M	55.73 M	—
Net Profit	22.49 M	50.87 M	39.78 M	45.56 M	49.48 M	—
EPS in Rs	0.39	0.88	0.69	0.79	0.85	—

Profit & Loss

Figures shown in M / B

	2025	2024	2023	2022
Sales	868.45 M	714.73 M	582.02 M	437.86 M
Operating Profit	208.47 M	190.83 M	192.03 M	120.19 M
Net Profit	158.69 M	145.49 M	128.85 M	181.47 M
EPS in Rs	2.74	2.51	2.23	3.14

Balance Sheet

Figures shown in M / B

	2025	2024	2023	2022
Total Assets	1.27 B	999.2 M	811.45 M	673.87 M
Total Liabilities	401.41 M	340.05 M	344.46 M	271.03 M
Equity	870.22 M	659.15 M	466.99 M	402.84 M
Current Assets	907.01 M	579.25 M	451.07 M	400.29 M
Current Liabilities	252.13 M	175.08 M	163.78 M	78.88 M

Cash Flow

Last available yearly cash flow history

	2025	2024	2023	2022
Operating CF	348.2 M	219.82 M	219.39 M	144.47 M
Investing CF	-39.65 M	-67.48 M	-46.44 M	-141.83 M
Financing CF	-9.05 M	-11 M	-105.55 M	6.84 M
Free CF	347.89 M	218.67 M	219.07 M	144.29 M
Capex	-0.31 M	-1.15 M	-0.31 M	-0.17 M

5Y Margin & Growth History

Last 5 year derived history from yfinance annual statements

	2024	2023	2022	2021
Revenue Growth %	22.8%	32.93%	—	—
Earnings Growth %	12.91%	-28.99%	—	—
Profit Margin %	20.36%	22.14%	41.44%	—
Operating Margin %	26.7%	32.99%	27.45%	—
Gross Margin %	78.06%	79.17%	80.93%	—
EBITDA Margin %	32.66%	38.06%	33.54%	—

Dividend & Split History

Latest dividend and stock split events stored from yfinance

Dividend History

No dividend history available.

Stock Splits

No stock split history available.

Shareholding Pattern

Shares and value shown in M / B

Holder Name	Type	Shares	Value	% Out	Report Date
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund	Mutual Fund	1.01 M	$27.96 M	0.02%	2026-02-28
iShares Trust-iShares Core S&P Small-Cap ETF	Mutual Fund	2.39 M	$66.42 M	0.04%	2026-01-31
American Century ETF Trust-Avantis U.S. Small Cap Value ETF	Mutual Fund	1.61 M	$44.58 M	0.03%	2026-01-31
iShares Trust-iShares Russell 2000 ETF	Mutual Fund	1.04 M	$28.77 M	0.02%	2026-01-31
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund	Mutual Fund	0.42 M	$11.75 M	0.01%	2026-01-31
Blackrock Inc.	Institutional	7.09 M	$196.64 M	0.12%	2025-12-31
Vanguard Group Inc	Institutional	4.81 M	$133.52 M	0.08%	2025-12-31
FMR, LLC	Institutional	3.11 M	$86.35 M	0.05%	2025-12-31
American Century Companies Inc	Institutional	1.84 M	$51.09 M	0.03%	2025-12-31
Dimensional Fund Advisors LP	Institutional	1.83 M	$50.78 M	0.03%	2025-12-31
State Street Corporation	Institutional	1.66 M	$46.1 M	0.03%	2025-12-31
LSV Asset Management	Institutional	1.66 M	$45.97 M	0.03%	2025-12-31
Arrowstreet Capital, Limited Partnership	Institutional	1.49 M	$41.38 M	0.03%	2025-12-31
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund	Mutual Fund	1.4 M	$38.83 M	0.02%	2025-12-31
Geode Capital Management, LLC	Institutional	1.27 M	$35.25 M	0.02%	2025-12-31